AU2023223327B2 - POLYMORPHIC FORM OF REDUCED β-NICOTINAMIDE MONONUCLEOTIDE DISODIUM SALT, AND PREPARATION METHOD THEREFOR AND USE THEREOF - Google Patents

POLYMORPHIC FORM OF REDUCED β-NICOTINAMIDE MONONUCLEOTIDE DISODIUM SALT, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Info

Publication number
AU2023223327B2
AU2023223327B2 AU2023223327A AU2023223327A AU2023223327B2 AU 2023223327 B2 AU2023223327 B2 AU 2023223327B2 AU 2023223327 A AU2023223327 A AU 2023223327A AU 2023223327 A AU2023223327 A AU 2023223327A AU 2023223327 B2 AU2023223327 B2 AU 2023223327B2
Authority
AU
Australia
Prior art keywords
crystal
crystal form
disodium salt
reduced
pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2023223327A
Other languages
English (en)
Other versions
AU2023223327A1 (en
Inventor
Liulei CHANG
Xing Gao
Yinshan LI
Jialing Liu
Qiang Shen
Qinyuan XU
Jianjun Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Effepharm (shanghai) Co Ltd
Original Assignee
Effepharm Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effepharm Shanghai Co Ltd filed Critical Effepharm Shanghai Co Ltd
Publication of AU2023223327A1 publication Critical patent/AU2023223327A1/en
Application granted granted Critical
Publication of AU2023223327B2 publication Critical patent/AU2023223327B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/002—Preparations for repairing the hair, e.g. hair cure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Birds (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
AU2023223327A 2022-02-23 2023-02-09 POLYMORPHIC FORM OF REDUCED β-NICOTINAMIDE MONONUCLEOTIDE DISODIUM SALT, AND PREPARATION METHOD THEREFOR AND USE THEREOF Active AU2023223327B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210168280.1 2022-02-23
CN202210168280.1A CN115368423B (zh) 2022-02-23 2022-02-23 还原型β-烟酰胺单核苷酸二钠盐的多晶型及其制法和用途
PCT/CN2023/075226 WO2023160405A1 (zh) 2022-02-23 2023-02-09 还原型β‐烟酰胺单核苷酸二钠盐的多晶型及其制法和用途

Publications (2)

Publication Number Publication Date
AU2023223327A1 AU2023223327A1 (en) 2024-09-12
AU2023223327B2 true AU2023223327B2 (en) 2025-10-09

Family

ID=84060296

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023223327A Active AU2023223327B2 (en) 2022-02-23 2023-02-09 POLYMORPHIC FORM OF REDUCED β-NICOTINAMIDE MONONUCLEOTIDE DISODIUM SALT, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Country Status (9)

Country Link
US (1) US12570683B2 (https=)
EP (1) EP4484438A1 (https=)
JP (1) JP7762933B2 (https=)
KR (1) KR20240167631A (https=)
CN (2) CN115368423B (https=)
AU (1) AU2023223327B2 (https=)
CA (1) CA3244879A1 (https=)
NZ (1) NZ813980A (https=)
WO (1) WO2023160405A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115368423B (zh) 2022-02-23 2025-05-09 音芙医药科技(上海)有限公司 还原型β-烟酰胺单核苷酸二钠盐的多晶型及其制法和用途
WO2023179793A1 (zh) * 2022-03-25 2023-09-28 成都嘉葆药银医药科技有限公司 一种1H-吡咯并[2,3-c]吡啶类化合物的晶型及其制备方法
CN119320416B (zh) * 2023-11-10 2026-01-06 音芙医药科技(上海)有限公司 还原型β-烟酰胺单核苷酸钙盐的多晶型及其制法和用途
CN119978042B (zh) * 2023-11-10 2025-09-09 音芙医药科技(上海)有限公司 还原型β-烟酰胺单核苷酸钙盐的无定型及其制法和用途
WO2025142856A1 (ja) * 2023-12-25 2025-07-03 株式会社カネカ 還元型β－ニコチンアミドモノヌクレオチドのカルシウム塩及びその製造方法
WO2025142857A1 (ja) * 2023-12-25 2025-07-03 株式会社カネカ 還元型β－ニコチンアミドモノヌクレオチドの塩及びその製造方法
CN120424148B (zh) * 2024-02-02 2025-10-17 音芙医药科技(上海)有限公司 还原型β-烟酰胺单核苷酸盐及其组合物、制法和用途
CN118546191A (zh) * 2024-07-29 2024-08-27 邦泰生物工程(深圳)有限公司 还原型β-烟酰胺单核苷酸一钠盐晶型及其制备方法和应用
WO2026075119A1 (ja) * 2024-10-04 2026-04-09 株式会社カネカ 還元型ニコチンアミドモノヌクレオチドの製造方法
CN119143826B (zh) * 2024-11-19 2025-03-28 邦泰生物工程(深圳)有限公司 还原型β-烟酰胺单核苷酸二钠盐无定型化合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107613990A (zh) * 2015-03-27 2018-01-19 康奈尔大学 烟酰胺单核苷酸的有效合成
CN110845548A (zh) * 2019-11-22 2020-02-28 武汉一若生物材料有限公司 一种制备β-烟酰胺单核苷酸及其钠盐的方法
CN113490676A (zh) * 2019-11-19 2021-10-08 清华大学 Nmn衍生物的合成方法和nmn及其衍生物的医学应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6352825B2 (ja) 2015-01-23 2018-07-04 株式会社ベスビオ 化粧料
KR20250080927A (ko) 2018-05-15 2025-06-05 점프스타트 퍼틸리티 피티와이 엘티디 노화방지제로서의 니코틴산 모노뉴클레오타이드의 무기 염
AU2019314476A1 (en) 2018-08-01 2021-02-25 Roland Dolle Quaternary ammonium salts of nicotinic acid and nicotinamide mononucloetides and ribosides as anti-aging agents
CN109350622A (zh) 2018-10-17 2019-02-19 深圳市龙格生技术有限公司 烟酰胺核糖及其衍生物与吡咯喹啉醌及其钠盐的组合工艺
CN112538101B (zh) * 2020-08-13 2026-02-03 常州博海威医药科技股份有限公司 一种β烟酰胺单核苷酸的新晶型及其制备方法和用途
CN114075582A (zh) 2020-08-18 2022-02-22 弈柯莱生物科技(上海)股份有限公司 一种d-核糖-5-磷酸的制备方法和应用
CN113332304A (zh) 2021-06-08 2021-09-03 深圳市旷逸生物科技有限公司 烟酰胺单核苷酸在制备心肌缺血再灌注损伤药物中的应用
CN113292619B (zh) * 2021-06-18 2022-04-22 邦泰生物工程(深圳)有限公司 烟酰胺单核苷酸-异烟碱共晶体及其组合物
CN115368423B (zh) * 2022-02-23 2025-05-09 音芙医药科技(上海)有限公司 还原型β-烟酰胺单核苷酸二钠盐的多晶型及其制法和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107613990A (zh) * 2015-03-27 2018-01-19 康奈尔大学 烟酰胺单核苷酸的有效合成
CN113490676A (zh) * 2019-11-19 2021-10-08 清华大学 Nmn衍生物的合成方法和nmn及其衍生物的医学应用
CN110845548A (zh) * 2019-11-22 2020-02-28 武汉一若生物材料有限公司 一种制备β-烟酰胺单核苷酸及其钠盐的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS SERVICE: "RN:108347-85-9", 《DATABASE REGISTRY[ONLINE]》, 30 May 1987 (1987-05-30) *
LIU YAO, et al.: "Engineering the biomimetic cofactors of NMNH for cytochrome P450 BM3 based on binding conformation refinement", RSC ADVANCES, vol. 11, no. 20, 2021, pages 12036 - 12042 *
YAN LIU: "Reduced Nicotinamide Mononucleotide (NMNH) Potently Enhances NAD+ and Suppresses Glycolysis, the TCA Cycle, and Cell Growth", 《J. PROTEOME RES.》, vol. 20, 1 April 2021 (2021-04-01), pages 2596 *

Also Published As

Publication number Publication date
CN118525027A (zh) 2024-08-20
US20250163092A1 (en) 2025-05-22
EP4484438A1 (en) 2025-01-01
JP7762933B2 (ja) 2025-10-31
CN115368423A (zh) 2022-11-22
CA3244879A1 (en) 2025-06-13
NZ813980A (en) 2026-01-30
US12570683B2 (en) 2026-03-10
KR20240167631A (ko) 2024-11-27
AU2023223327A1 (en) 2024-09-12
JP2025508874A (ja) 2025-04-10
WO2023160405A1 (zh) 2023-08-31
CN115368423B (zh) 2025-05-09

Similar Documents

Publication Publication Date Title
AU2023223327B2 (en) POLYMORPHIC FORM OF REDUCED β-NICOTINAMIDE MONONUCLEOTIDE DISODIUM SALT, AND PREPARATION METHOD THEREFOR AND USE THEREOF
KR102522895B1 (ko) Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법
BRPI0807319B1 (pt) Base de minociclina cristalina forma 1, processo para preparar base de minociclina cristalina forma i, base de minociclina cristalina forma ii, processo para preparar base de minociclina cristalina forma ii, base de minociclina cristalina forma iii e processo para preparar base de minociclina cristalina forma iii
EP3453708A1 (en) Process for the preparation of 5-chloro-n-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n-2-(isopropylsulfonyl)phenyl)-2,4-diamine di-hydrochloride
EP3205653B1 (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
US20250388616A1 (en) POLYMORPHIC FORM OF REDUCED ß-NICOTINAMIDE MONONUCLEOTIDE CALCIUM SALT, AND PREPARATION METHOD AND USE THEREFOR
WO2018137502A1 (zh) 一种丹酚酸a的晶型及其制备方法
TWI656116B (zh) Crystal form of 9-aminomethyl substituted tetracycline compound and preparation method thereof
CN113121456B (zh) 一种阿昔莫司尿素共晶
CN111094313B (zh) 盐酸伊达比星一水合物的晶型
KR20170060035A (ko) 나트륨 글루코스 공동운반체 2 억제제의 ｌ- 프롤린 화합물, 및 ｌ- 프롤린 화합물의 모노하이드레이트 및 결정
US20190218184A1 (en) Novel Crystalline Form of Lenvantinib Mesylate and Process of Preparation Thereof
US9834540B2 (en) Omeprazole Sodium semihydrate and preparation method thereof
CN110804017A (zh) 磺酰脲化合物与二甲双胍成盐、制备方法和应用
WO2021208055A1 (zh) 一种噻吩并哒嗪类化合物的晶型及其制备方法和应用
CN109053717B (zh) 一种罗格列酮龙胆酸盐及其制备方法
HK40121709A (zh) 还原型β-烟醯胺单核苷酸钙盐的无定型及其制法和用途
WO2025097718A1 (zh) 还原型β-烟酰胺单核苷酸钙盐的无定型及其制法和用途
WO2022224269A1 (en) Co-crystals, salts and solid forms of niraparib
CN119019372A (zh) 一种盐酸替匹嘧啶晶体的制备方法
HK40003121A (en) Process for the preparation of 5-chloro-n-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n-2-(isopropylsulfonyl)phenyl)-2,4-diamine di-hydrochloride
EP3052499A1 (en) Crystalline abacavir hydrochloride monohydrate and process for its preparation
CN104557961A (zh) 7-乙基-10-羟基喜树碱晶型及其制备方法与应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)